search
Back to results

Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes

Primary Purpose

Recurrent Genital Herpes

Status
Completed
Phase
Phase 3
Locations
Australia
Study Type
Interventional
Intervention
Famciclovir
Sponsored by
Novartis
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Recurrent Genital Herpes focused on measuring genital herpes, herpes, famciclovir

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All Sexes

Inclusion Criteria: Diagnosis of genital herpes Had at least 2 recurrences in past 12 months or 1 recurrence in past 6 months Exclusion Criteria: - Currently taking suppressive herpes antiviral therapy Females who are pregnant, breast feeding or planning to become pregnant during study History of allergy to famciclovir or similar products (e.g. aciclovir, valaciclovir) Other protocol-defined exclusion criteria may apply.

Sites / Locations

  • Novartis Investigative Site

Outcomes

Primary Outcome Measures

Estimated probability being not lesion-free(i.e. not healed) 5.5 elapsed days (132 hours) after patient self-initiation therapy.

Secondary Outcome Measures

Safety and tolerability assessed by AEs.
Time between recurrences of genital herpes.
Proportion of aborted (i.e. lesions did not appear)genital herpes recurrences. Change from baseline in symptoms or impairment. Change form baseline in functioning or disability.

Full Information

First Posted
September 13, 2005
Last Updated
August 14, 2013
Sponsor
Novartis
search

1. Study Identification

Unique Protocol Identification Number
NCT00171990
Brief Title
Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes
Official Title
Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes
Study Type
Interventional

2. Study Status

Record Verification Date
August 2013
Overall Recruitment Status
Completed
Study Start Date
January 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
February 2006 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Novartis

4. Oversight

5. Study Description

Brief Summary
This is a phase III, multicenter, randomized, double-blind, parallel-group study to compare the efficacy and safety of a two-day treatment with famciclovir (500 mg loading dose followed by 250 mg 12-hourly) to standard five-day treatment with famciclovir (125 mg 12-hourly) in patients with active recurrent genital herpes. This study is not recruiting patients in the United States.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Recurrent Genital Herpes
Keywords
genital herpes, herpes, famciclovir

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
1461 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Famciclovir
Primary Outcome Measure Information:
Title
Estimated probability being not lesion-free(i.e. not healed) 5.5 elapsed days (132 hours) after patient self-initiation therapy.
Secondary Outcome Measure Information:
Title
Safety and tolerability assessed by AEs.
Title
Time between recurrences of genital herpes.
Title
Proportion of aborted (i.e. lesions did not appear)genital herpes recurrences. Change from baseline in symptoms or impairment. Change form baseline in functioning or disability.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Eligibility Criteria
Inclusion Criteria: Diagnosis of genital herpes Had at least 2 recurrences in past 12 months or 1 recurrence in past 6 months Exclusion Criteria: - Currently taking suppressive herpes antiviral therapy Females who are pregnant, breast feeding or planning to become pregnant during study History of allergy to famciclovir or similar products (e.g. aciclovir, valaciclovir) Other protocol-defined exclusion criteria may apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharma AG
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Chair
Facility Information:
Facility Name
Novartis Investigative Site
City
North Ryde
Country
Australia

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes

We'll reach out to this number within 24 hrs